Access count of this item: 60

Files in This Item:
File Description SizeFormat 
oncotarget.8620.pdf5.7 MBAdobe PDFView/Open
Title: Pattern of RECK CpG methylation as a potential marker for predicting breast cancer prognosis and drug-sensitivity
Authors: Shi, Gongping
Yoshida, Yoko  kyouindb  KAKEN_id
Yuki, Kanako
Nishimura, Tomomi
Kawata, Yukiko
Kawashima, Masahiro  kyouindb  KAKEN_id
Iwaisako, Keiko
Yoshikawa, Kiyotsugu
Kurebayashi, Junichi
Toi, Masakazu
Noda, Makoto  kyouindb  KAKEN_id
Author's alias: 吉田, 陽子
戸井, 雅和
野田, 亮
Keywords: Breast cancer
CpG island
DNA methylation
Issue Date: 6-Apr-2016
Publisher: Impact Journals LLC
Journal title: Oncotarget
Volume: 7
Issue: 50
Start page: 82158
End page: 82169
Abstract: The membrane-anchored glycoprotein RECK negatively regulates multiple metalloproteinases and is frequently downregulated in tumors. Forced RECK expression in cancer cells results in suppression of tumor angiogenesis, invasion, and metastasis in xenograft models. A previous methylome study on breast cancer tissues detected inverse correlation between RECK CpG methylation (in an intron-1 region) and relapse-free survival. In this study, we focused on another region of the RECK CpG island (a promoter/exon-1 region) and found an inverse correlation between its methylation and RECK-inducibility by an HDAC inhibitor, MS275, among a panel of breast cancer cell lines (n=15). In clinical samples (n=62), RECK intron-1 methylation was prevalent among luminal breast cancers as reported previously (26 of 38 cases; 68%) and particularly enriched in tumors of the ER+PR- subclass (10 of 10 cases) and of higher histological grades (Grade 2 and 3; 28 of 43 cases; P=0.006). In about a half of these cases, promoter/exon-1 methylation was absent, and hence, RECK may be inducible by certain drugs such as MS275. Our results indicate the value of combined use of two RECK methylation markers for predicting prognosis and drugsensitivity of breast cancers.
Rights: All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
DOI(Published Version): 10.18632/oncotarget.8620
PubMed ID: 27058625
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.